Data may prove too little too late for the antibody drug conjugate, as GSK takes a cautious stance over future commercial viability.
Newly unveiled Phase III data could help GSK bring its multiple myeloma therapy Blenrep back to the market but it will await a further positive readout before making a decision.
GSK’s antibody drug conjugate Blenrep (belantamab mafodotin) was removed from the US market in late 2022 when it failed to...
Create an account to read this article
Already a subscriber?
Licensing a BTK inhibitor for progressive MS previously held by Biogen, Zenas says Phase III orelabrutinib can stave off disability related with disease progression.
The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.
With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.
The company announced positive Phase II data for umedaptanib pegol and plans to move it into Phase III development in fiscal year 2026.
Japan's latest Nobel Prize win sparks hopes for renewed investment in biopharma R&D by the national government, including in a venture co-founded by the winner.
Speakers at ARM’s Cell and Gene Meeting on the Mesa highlighted challenges of CAR-T’s evolution from niche to mainstream therapy given health care providers’ limited capacity to deliver the complex care associated with the products.
With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.
